Related Experiment Video
Updated: May 22, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
Published on: December 27, 2013
Hyaluronic acid-modified PLGA nanoparticles for enhanced ocular drug delivery
Sa Huang1,2, Tianyu Tang2,3, Huashen He2,3
1College of Pharmacy, Guilin Medical University, Guilin, People's Republic of China.
Aim:
To develop hyaluronic acid (HA)-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles (HA-PLGA NPs) for enhanced triamcinolone acetonide (TA) ocular delivery.
Methods:
HA-PLGA NPs were prepared via solvent evaporation. Physicochemical properties, in vitro corneal permeation, and in vivo pharmacokinetics in rabbit aqueous humour were evaluated.
Results:
HA modification significantly increased encapsulation efficiency from 22.26 ± 0.8% to 62.87 ± 3.9% (w/w) and drug loading from 2.21 ± 0.08% to 6.09 ± 0.38% (w/w). Apparent permeability coefficient increased from 2.33 ± 0.14 to 9.28 ± 0.58 (×10-6cm·s-1). In vivo, HA-PLGA NPs achieved a 7.2-fold higher area under the curve (AUC0→360) (8.06 μg·mL-1·min) compared to unmodified nanoparticles.
Conclusions:
HA-PLGA NPs provide a high-efficiency, non-invasive platform for treating posterior segment diseases by overcoming ocular barriers through bioadhesion.
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Ophthalmic Drug Delivery Systems
Modified-Release Drug Delivery Systems: Site-Targeted
Modified-Release Drug Delivery Systems: Stimuli-Activated
Modified-Release Drug Delivery Systems: Rate-Programmed II
Oral Drug Delivery Systems: Delayed-Release Systems

